Announcements Trials
Browse Landscape

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 23Observational 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Burkitt Lymphoma 2Recurrence 1Hematologic Neoplasms 1

Interventions

Psychiatric Rehabilitation 7Flow Cytometry 6Therapeutics 5Surveys and Questionnaires 5Microarray Analysis 5Gene Expression Profiling 5Vincristine 4Polymerase Chain Reaction 4Methotrexate 4Daunorubicin 4Cytogenetic Analysis 4Amplified Fragment Length Polymorphism Analysis 4ponatinib 3fludarabine 3Watchful Waiting 3Prednisone 3Observation 3Mercaptopurine 3Interviews as Topic 3Inotuzumab Ozogamicin 3Immunologic Techniques 3Immunoenzyme Techniques 3Cytarabine 3Cyclophosphamide 3tisagenlecleucel 2pegaspargase 2fish oil triglycerides 2blinatumomab 2In Situ Hybridization, Fluorescence 2Imatinib Mesylate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Inotuzumab Ozogamicin × Clear all
NCT07238907 2025-11-25

A Multi-center Retrospective Study of INO Treating B-ALL

Ruijin Hospital

Active not recruiting
102 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05597085 2025-02-04

A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment

Pfizer

Completed
32 enrolled 31 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04456959 2022-09-28

InO

Pfizer

Completed
28 enrolled 55 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡